S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00336947
Recruitment Status : Unknown
Verified December 2008 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : June 15, 2006
Last Update Posted : May 15, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as S-1 and tegafur-uracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving S-1 or tegafur-uracil after surgery, chemotherapy, biological therapy, and/or radiation therapy may kill any remaining tumor cells. It is not yet known whether S-1 is more effective than tegafur-uracil in treating head and neck cancer.

PURPOSE: This randomized phase III trial is studying S-1 to see how well it works compared with tegafur-uracil in treating patients with previously treated stage III or stage IV head and neck cancer.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Drug: tegafur-gimeracil-oteracil potassium Drug: tegafur-uracil Procedure: adjuvant therapy Phase 3

Detailed Description:


  • Compare the disease-free survival rate in patients with definitively treated stage III or IV squamous cell carcinoma of the head and neck treated with adjuvant chemotherapy comprising S-1 vs tegafur-uracil (UFT).

OUTLINE: This is a randomized, controlled, multicenter study. Patients are stratified according to primary site, disease stage, type of prior definitive treatment, and participating center. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral S-1 once daily on days 1-14. Courses repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity.
  • Arm II:Patients receive oral tegafur-uracil (UFT) once daily on days 1-21. Courses repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study
Study Start Date : April 2006
Estimated Primary Completion Date : March 2012

Primary Outcome Measures :
  1. Disease-free survival

Secondary Outcome Measures :
  1. Relapse-free survival
  2. Overall survival
  3. Adverse effects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (SCCHN)

    • Stage III or IV disease
    • Primary tumor in the mesopharynx, hypopharynx, larynx (except T3 N0 tumors of the glottis), oral cavity, or maxillary sinus
  • Completed definitive treatment for SCCHN within the past 3 months, that included any of the following:

    • Surgery
    • Chemotherapy
    • Biologic therapy
    • Radiotherapy (e.g., radiotherapy in combination with chemotherapy or pre- or postoperative radiotherapy)
    • Any other treatment
  • No clinical evidence of locoregional tumors or distant metastasis within 3 months after the completion of definitive treatment


  • ECOG performance status 0-1
  • WBC ≥ 3,500/mm^3 AND ≤ 12,000/mm^3
  • Neutrophil count ≥ 2,000/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9 g/dL
  • AST and ALT < 100 IU/L
  • Bilirubin < 1.5 mg/dL
  • Creatinine < 1.2 mg/dL
  • No uncontrolled cardiovascular disease
  • No interstitial pneumonia or pulmonary fibrosis
  • Must have sufficient oral intake


  • See Disease Characteristics
  • No concurrent biologic therapy, radiotherapy, other chemotherapy, or any other therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00336947

Aichi Cancer Center
Nagoya, Aichi, Japan, 464-8681
Fujita Health University
Toyoake, Aichi, Japan, 470-11
Akita University Hospital
Akita City, Akita, Japan, 010-854
Tokyo Dental College Ichikawa General Hospital
Ichikawa, Chiba, Japan, 272-8513
Ehime University Hospital
Toon, Ehime, Japan, 791-0295
National Kyushu Cancer Center
Fukuoka-shi, Fukuoka, Japan, 811-1395
Gifu University Graduate School of Medicine
Gifu-shi, Gifu, Japan, 501-1194
Gunma University Graduate School of Medicine
Maebashi, Gunma, Japan, 371-8511
Hokkaido University Hospital
Sapporo, Hokkaido, Japan, 060-8637
Hyogo Cancer Center
Akashi City, Hyogo, Japan, 673-8558
National Hospital Organization - Himeji Medical Center
Himeji-shi, Hyogo, Japan, 650-0017
Kanazawa Medical University
Kanazawa, Ishikawa, Japan, 920-0934
Iwate Medical University Hospital
Morioka-shi, Iwate, Japan, 020-8505
Kagoshima City Hospital
Kagoshima City, Kagoshima, Japan, 892-8580
Yokohama Rosai Hospital
Yokohama, Kanagawa, Japan, 222-0036
Yokohama City University
Yokohama, Kanagawa, Japan, 232-0024
Kumamoto University Medical School
Kumamoto City, Kumamoto, Japan, 860-8556
Mie University Graduate School of Medicine
Tsu, Mie, Japan, 514
Tohoku University Graduate School of Medicine
Sendai, Miyagi, Japan, 980-8574
Miyazaki Medical College University of Miyazaki
Miyazaki-gun, Miyazaki, Japan, 889-1692
Tenri Hospital
Tenri, Nara, Japan, 632-8552
Niigata Prefectural Central Hospital
Joetsu, Niigata, Japan, 943-0192
Kawasaki Medical School
Kurashiki, Okayama, Japan, 701-01
Kinki University School of Medicine
Osakasayama, Osaka, Japan, 589-8511
Shimane University Hospital
Izumo, Shimane, Japan, 693-8501
Seirei Hamamatsu General Hospital
Hamamatsu, Shizuoka, Japan, 430-8558
Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, Japan, 431-31
Saiseikai Utsunomiya Hospital
Utsunomiya, Tochigi, Japan, 321-0974
Tokyo Medical University Hachioji Medical Center
Hachioji, Tokyo, Japan, 193-0998
National Tokyo Medical Center
Menguro-ku, Tokyo, Japan, 152-8902
Kyorin University School of Medicine - Mitaka Campus
Mitaka-shi, Tokyo, Japan, 181-8611
Ome Municipal General Hospital
Ome-shi, Tokyo, Japan, 198-0042
Tottori University Hospital
Yonago-shi, Tottori, Japan, 683-8504
Wakayama Medical University
Wakayama-shi, Wakayama, Japan, 641-8510
Interdiciplinary Graduate School of Medicine and Engineering
Yamanashi, Yamagata, Japan, 409-3898
University of Fukui Hospital
Fukui, Japan, 910-1193
Fukushima Medical University Hospital
Fukushima, Japan, 960-1295
Kagoshima University
Kagoshima, Japan, 890-8520
Osaka General Medical Center
Osaka, Japan, 558-0056
Osaka City University
Osaka, Japan, 558-8585
Saitama Cancer Center
Saitama, Japan, 362-0806
Juntendo University School of Medicine
Tokyo, Japan, 113-8421
Tokyo Medical and Dental University
Tokyo, Japan, 113-8510
Nippon Medical School
Tokyo, Japan, 113
Cancer Institute Hospital of Japanese Foundation for Cancer Research
Tokyo, Japan, 135-8550
Tokyo Medical University
Tokyo, Japan, 160-0023
Keio University School of Medicine
Tokyo, Japan, 160-8582
International Medical Center of Japan
Tokyo, Japan, 162-8655
Sponsors and Collaborators
Yokohama City University
Study Chair: Mamoru Tsukuda, MD Yokohama City University

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00336947     History of Changes
Other Study ID Numbers: YCU-BRI-HN-05-01
CDR0000486874 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: June 15, 2006    Key Record Dates
Last Update Posted: May 15, 2013
Last Verified: December 2008

Keywords provided by National Cancer Institute (NCI):
stage III squamous cell carcinoma of the hypopharynx
stage IV squamous cell carcinoma of the hypopharynx
stage III squamous cell carcinoma of the larynx
stage IV squamous cell carcinoma of the larynx
stage III squamous cell carcinoma of the lip and oral cavity
stage IV squamous cell carcinoma of the lip and oral cavity
stage III squamous cell carcinoma of the oropharynx
stage IV squamous cell carcinoma of the oropharynx
stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents